The emerging markets in CE, SE and Eastern Europe include Romania, Poland, Hungary, Turkey, Serbia.

The emerging markets in CE, SE and Eastern Europe include Romania, Poland, Hungary, Turkey, Serbia.
The emerging markets in CE, SE and Eastern Europe include Romania, Poland, Hungary, Turkey, Serbia, Lithuania.

Monday, 12 January 2015

Pharmaceuticals production in Romania


Pharma production in Romania is a dynamic sector. According to official statistic data, in October 2014 compared to October 2013, the manufacturing of basic pharmaceutical products and pharmaceutical preparations in Romania has increased by 16.8%.

In the first nine months of 2014, the value of the new orders index in the manufacturing of basic pharmaceutical products and pharmaceutical preparations in Romania has increased slightly compared to the first nine months of 2013.

In Romania, there are over 120 manufacturers of pharmaceutical products with a cumulated net turnover of over 600 million EUR in 2012. Some of the main ones are: Terapia Ranbaxy, Zentiva, Antibiotice, Sandoz or Gedeon Richter.

Antibiotice, controlled by the Ministry of Health, is a significant pharmaceuticals player and the largest OTC producer in Romania. The company has in its portfolio approximately 140 drugs that cover a wide range of therapeutic areas (mainly for cardiovascular, anti-infectious and central nervous system). In the first semester of 2014 compared to the similar period of 2013, Antibiotice has recorded a sales increase of 6%. Antibiotice has registered in 2013 a net turnover of 72 million EUR, up by over 5% compared to 2012. The company is listed on the Bucharest Stock Exchange and has some 1,500 employees.

Other independent OTC producers in Romania are: Fiterman Farma, Bio Eel, Slavia Pharm, Biofarm, Arena Group or Magistra C&C.

Some examples of recent or in-progress investments and developments in the sector of the pharmaceuticals manufacturing in Romania are:


  • Antibiotice invests ten million EUR, during the period 2014 - 2016, in a new production unit of ointments and suppositories in Iasi. The company plans to invest some 40 million EUR in the next six years to increase the production facilities and to develop new pharmaceutical products.
  • Terapia Ranbaxy, the local subsidiary of Ranbaxy Laboratories, has launched seven new non-prescription drugs and, as a result, its sales have increased by 9.5% in the first six months of 2014 compared to the same period of 2013. Terapia Ranbaxy produces drugs in the cardiovascular, central nervous system, anti-infective, gastrointestinal and musculoskeletal segments. Terapia Ranbaxy has reported a net profit of almost 25 million EUR in 2013, up by approximately 14% compared to 2012.
  • Pfizer invests approximately four million EUR in the packaging line of its manufacturing unit of supplements located in Cluj Napoca. The works are expected to be finalised in 2015. At present, the unit has the packaging capacity of six million boxes per year.
In case you are interested to contact local producers or you are interested in more details about the sector, feel free to contact our team at:
email: europa@frdcenter.ro
tel: +4021 411 1459 / 60 / 61

No comments:

Post a Comment

Note: only a member of this blog may post a comment.